Metastasis

Results: 1617



#Item
1#4503 A Small Molecule Glycomimetic Antagonist of E-selectin (GMIPrevents Pancreatic Tumor Metastasis and Offers Improved Efficacy of Chemotherapy Maria M. Steele1, BS, Prakash Radhakrishnan1, PhD, John L. Magnani

#4503 A Small Molecule Glycomimetic Antagonist of E-selectin (GMIPrevents Pancreatic Tumor Metastasis and Offers Improved Efficacy of Chemotherapy Maria M. Steele1, BS, Prakash Radhakrishnan1, PhD, John L. Magnani

Add to Reading List

Source URL: glycomimetics.com

Language: English - Date: 2014-04-10 23:45:38
    2Quantitative image-based phenotypes for cancer metastasis systems biology Joel S. Bader, Ph.D. Professor, Biomedical Engineering Johns Hopkins University

    Quantitative image-based phenotypes for cancer metastasis systems biology Joel S. Bader, Ph.D. Professor, Biomedical Engineering Johns Hopkins University

    Add to Reading List

    Source URL: www.alterlab.org

    Language: English - Date: 2017-01-31 12:45:46
      3A	
  small	
  molecule	
  glycomime.c	
  antagonist	
   of	
  E-­‐selec.n	
  and	
  CXCR4	
  (GMI-­‐1359)	
   delays	
  pancrea.c	
  tumor	
  metastasis	
  and	
   significantly	
  alters	
  the

      A  small  molecule  glycomime.c  antagonist   of  E-­‐selec.n  and  CXCR4  (GMI-­‐1359)   delays  pancrea.c  tumor  metastasis  and   significantly  alters  the

      Add to Reading List

      Source URL: glycomimetics.com

      Language: English - Date: 2016-04-22 18:58:30
        4Why we focus on Metastasis & Invasion Around 90% of cancer deaths are attributable to invasion and metastasis. Metastasis is the spread of disease from one organ or part to another not directly connected with the primary

        Why we focus on Metastasis & Invasion Around 90% of cancer deaths are attributable to invasion and metastasis. Metastasis is the spread of disease from one organ or part to another not directly connected with the primary

        Add to Reading List

        Source URL: www.bci.qmul.ac.uk

        - Date: 2016-04-04 11:36:10
          5Nota de Prensa LA FDA APRUEBA DENOSUMAB PARA LA PREVENCIÓN DE EVENTOS ESQUELÉTICOS EN PACIENTES CON METÁSTASIS ÓSEAS DE TUMORES SÓLIDOS BARCELONA. (nov. 19, 2010) – La FDA ha aprobado denosumab, el primer y

          Nota de Prensa LA FDA APRUEBA DENOSUMAB PARA LA PREVENCIÓN DE EVENTOS ESQUELÉTICOS EN PACIENTES CON METÁSTASIS ÓSEAS DE TUMORES SÓLIDOS BARCELONA. (nov. 19, 2010) – La FDA ha aprobado denosumab, el primer y

          Add to Reading List

          Source URL: static.diariomedico.com

          - Date: 2010-11-30 08:40:44
            6A organotypic model of prostate tumor metastasis

            A organotypic model of prostate tumor metastasis

            Add to Reading List

            Source URL: www.ncibi.org

            - Date: 2010-08-05 12:07:05
              7Histopathologic Features that Influence the Detection of Occult Lymph Node Metastasis Using PET/CT Imaging with Anti-PSMA Df-IAB2M in Newly Diagnosed High Risk Prostate Cancer Patients. 89Zr-  Bernard M. Gburek1, Anthony

              Histopathologic Features that Influence the Detection of Occult Lymph Node Metastasis Using PET/CT Imaging with Anti-PSMA Df-IAB2M in Newly Diagnosed High Risk Prostate Cancer Patients. 89Zr- Bernard M. Gburek1, Anthony

              Add to Reading List

              Source URL: www.imaginab.com

              Language: English - Date: 2016-06-14 13:50:56
              8· METASTATIC BREAST CANCER ·  Assessing Treatment Response in Metastatic Breast Cancer Shlomit Strulov Shachar, MD, and Hyman B. Muss, MD  Abstract

              · METASTATIC BREAST CANCER · Assessing Treatment Response in Metastatic Breast Cancer Shlomit Strulov Shachar, MD, and Hyman B. Muss, MD Abstract

              Add to Reading List

              Source URL: gotoper-com.s3.amazonaws.com

              Language: English - Date: 2016-08-08 16:43:54
              9Media release, October 23, 2014  Stopping anti-CCL2 breast cancer treatment aggravates the disease Mohamed Bentires-Alj and his team at the Friedrich Miescher Institute for Biomedical Research (FMI) together with scienti

              Media release, October 23, 2014 Stopping anti-CCL2 breast cancer treatment aggravates the disease Mohamed Bentires-Alj and his team at the Friedrich Miescher Institute for Biomedical Research (FMI) together with scienti

              Add to Reading List

              Source URL: www.fmi.ch

              Language: English - Date: 2014-10-22 09:52:50
              10American Society for Radiation Oncology  Five Things Physicians and Patients Should Question Don’t initiate whole breast radiotherapy as a part of breast conservation therapy in women age ≥50 with early stage invasiv

              American Society for Radiation Oncology Five Things Physicians and Patients Should Question Don’t initiate whole breast radiotherapy as a part of breast conservation therapy in women age ≥50 with early stage invasiv

              Add to Reading List

              Source URL: mnoncology.com

              Language: English - Date: 2014-12-30 11:15:28